AU2020206021B2 — Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation

USPTO Abstract

The present invention relates to the field of treating iron deficiency with intravenous iron carbohydrate complexes such iron isomaltoside in subjects at risk of a cardiovascular adverse event, wherein the treatment of iron deficiency reduces the incidence of, or risk for, a cardiovascular adverse event in the subject. In another aspect, the invention provides a method for the reduction of P-wave dispersion/ duration for the management of atrial fibrillation or disorders associated with atrial fibrillation (e.g., heart failure, hypertension, heart valve disease, coronary artery disease, obesity, and diabetes mellitus) in an animal suffering from such a condition which comprises administering to such an animal a therapeutically effective amount of an iron agent via the oral, intramuscular or intravenous route.